NCT01495169

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

A Multicenter, Open-label, Sequential Cohort, Dose-escalation, 14-day Study to Explore the Tolerability and Pharmacokinetics of Iloperidone 12 to 24 mg/Day Followed by 26 Weeks of Flexible Dosing (6 to 24 mg/Day) in Adolescent Patients (Aged 12 to 17 Years)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Vanda Pharmaceuticals · Industry
• Sex: All
• Age: 12 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication

Conditions

• Safety and Tolerability of Iloperidone

Interventions

Type	Name	Description
DRUG	iloperidone (oral tablet)	iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)

Timeline

• Start date: 2011-10-01
• Primary completion: 2015-02-01
• Completion: 2015-02-01
• First posted: 2011-12-19
• Last updated: 2016-06-13

Locations

10 sites across 1 country: United States